Instil Bio (TIL) EBIT Margin (2020)

Instil Bio (TIL) posted quarterly EBIT Margin of 14828.85% for Q3 2020, down 35.6% quarter-over-quarter from 10935.71% in Q2 2020.

Instil Bio (TIL) EBIT Margin (2020) Analysis & Trends

Instil Bio's EBIT Margin history runs 1 years deep, the most recent figure standing at 14828.85% for Q3 2020.

In Q3 2020, EBIT Margin changed N/A year-over-year to 14828.85%; the TTM figure through Jun 2021 stood at 161484.62% (changed N/A YoY), while the FY2020 annual figure was 24379.71%, changed N/A from the prior year.
EBIT Margin for Q3 2020 stood at 14828.85%, down from 10935.71% in the prior quarter.
The five-year high for EBIT Margin was 8779.55% in Q1 2020, with the low at 14828.85% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	30.15%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	32.54%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-35.57%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	19.75%
10	Instil Bio	51.68 Mn	51.68 Mn	-	-

Download Data